Research
Cellular
Sodium-glucose cotransporter 2 (SGLT2) inhibitors provide cardiovascular and renal protection in patients with type 2 diabetes mellitus (T2DM).
Practitioners should consider SGLT2 inhibitors as a treatment option for cardiovascular and renal protection in T2DM patients.
StrongSupportsmedium confidence
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as noteworthy antihyperglycemic agents with concomitant CV and renal protection in T2DM patients.
Why this rating
The claim is supported by major large-scale outcome trials.
Source
Sodium–Glucose Cotransporter-2 Inhibition in Type 2 Diabetes Mellitus
Rinkoo Dalan · Cardiology in Review · 2018
DOI 10.1097/crd.0000000000000201
reviewCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →